Patents by Inventor Liming Liu
Liming Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190363540Abstract: Unique systems, methods, techniques and apparatuses of photovoltaic (PV) string power systems are disclosed. One exemplary embodiment is a PV power system comprising a plurality of PV strings and a floating DC-DC optimizer. The floating DC-DC optimizer comprises a first DC bus rail, a second DC bus rail, a plurality of input legs, each leg being coupled across the first DC bus rail and second DC bus rail, including two input leg semiconductor switches coupled at an input terminal, each input terminal being structured to receive an input current from an end of one PV string of the plurality of PV strings, and an output leg including two output leg semiconductor devices coupled at an output terminal.Type: ApplicationFiled: May 25, 2018Publication date: November 28, 2019Inventors: Zhiguo Pan, Sandeep Bala, Liming Liu, Yuxiang Shi
-
Patent number: 10393795Abstract: Unique systems, methods, techniques and apparatuses of semiconductor failure prognostication. One exemplary embodiment is a power converter comprising a semiconductor switch and a converter control system. The converter control system is configured to turn on the semiconductor switch, measure a first voltage and a current during reverse conduction, estimate junction temperature of the semiconductor device, turn off the semiconductor device, measure a second voltage after turning off the semiconductor device, determine a resistance value using the second voltage measurement, determine an expected resistance value, predict a failure of the semiconductor device using the resistance value and the expected resistance value, and transmit a semiconductor device failure warning.Type: GrantFiled: July 25, 2017Date of Patent: August 27, 2019Assignee: ABB Schweiz AGInventors: Eddy Aeloiza, Arun Kadavelugu, Joonas Puukko, Liming Liu, Jukka-Pekka Sjoroos
-
Publication number: 20190207550Abstract: A method for operating an electrical machine having a stator and having a rotor with permanent magnets, includes: running the electrical machine; determining, while performing the running of the electrical machine, whether the permanent magnets have been demagnetized; finding, while running the electrical machine, the q-axis responsive to a determination that the permanent magnets have been demagnetized; firing a current pulse through the stator, while running the electrical machine, when the q-axis reaches a desired position relative to a selected stator phase, wherein the current pulse is constructed to remagnetize the permanent magnets; and continuing to run the electrical machine.Type: ApplicationFiled: December 30, 2017Publication date: July 4, 2019Inventors: Alessandro Castagnini, Darren Tremelling, Elio Alberto Perigo, Giulio Secondo, Liming Liu
-
Publication number: 20190201584Abstract: A porous bionic skull repairing material includes a polymer material, whose structure is consistent with that of a human skull. The surface layers of the porous bionic skull repairing material are dense layers which are composed of non-degradable or degradable polymer materials and has blind holes having an asymmetric structure, and the inner layer of the porous bionic skull repairing material is a loose layer which has a porous structure. The repairing material can be molded by adopting a mixed mould pressing method or a 3D printing method, simulates a bone structure, with two dense sides and a loose middle, of a human skull to the greatest extent.Type: ApplicationFiled: December 27, 2018Publication date: July 4, 2019Applicant: Shandong Branden Medical Device Co.,LtdInventors: Haijun ZHANG, Liming LIU, Shoutao LU, Wenrui CAO, Hairong XU, Chao ZHOU, Yuxia YIN, Wenbo HOU, Cuihai DUAN, Guang LIU
-
Publication number: 20190192438Abstract: A method for preparing a degradable drug-loaded microsphere for embolization and a product obtained therefrom, includes the steps of: dissolving a degradable material in an organic solvent, then adding a drug and mixing well to form a suspension or solution; then pouring the drug-containing suspension or solution into an aqueous solution of polyvinyl alcohol, stirring, and thereafter adding water twice for dilution, to prepare the degradable drug-loaded microsphere. The microsphere prepared by the present invention has the advantages of having a controllable particle size, a high drug loading capacity, and a regular spherical shape, being convenient for sieve sizing and accurate particle-size indication, and being accurately targeted to an embolized blood vessel, and the like, and thus has a good application prospect in interventional embolization therapy.Type: ApplicationFiled: December 21, 2018Publication date: June 27, 2019Applicant: Shandong Rientech Medical Technology Co.,LtdInventors: Haijun ZHANG, Shoutao LU, Hairong XU, Liming LIU, Wenrui CAO, Maoquan LI, Chao ZHOU, Yuxia YIN, Cuihai DUAN, Wenbo HOU, Guang LIU
-
Patent number: 10308919Abstract: The present invention provides a recombinant strain, construction method thereof and a method for producing acid phosphatase using the recombinant strain. In the invention, the phosphatase gene is obtained from Pseudomonas aeruginosa by a molecular biology method, the constructed expression plasmid is transformed into E. coli BL21 (DE3). The purified enzyme and whole cells were used for the conversion of ascorbic acid to ascorbic acid-2-phosphate. Ascorbic acid-2-phosphate can be efficiently produced by controlling the ratio of substrates. When the conversion reaction is performed at pH 4.5 under 40° C. for 8 h, the output of ascorbic acid-2-phosphate reaches 54.8 g/L, the conversion is 42.9% and the space time yield is 6.9 g/L/h.Type: GrantFiled: December 21, 2016Date of Patent: June 4, 2019Assignee: JIANGNAN UNIVERSITYInventors: Liming Liu, Wei Song, Jing Wu, Kai Zheng, Xiulai Chen
-
Publication number: 20190033362Abstract: Unique systems, methods, techniques and apparatuses of semiconductor failure prognostication. One exemplary embodiment is a power converter comprising a semiconductor switch and a converter control system. The converter control system is configured to turn on the semiconductor switch, measure a first voltage and a current during reverse conduction, estimate junction temperature of the semiconductor device, turn off the semiconductor device, measure a second voltage after turning off the semiconductor device, determine a resistance value using the second voltage measurement, determine an expected resistance value, predict a failure of the semiconductor device using the resistance value and the expected resistance value, and transmit a semiconductor device failure warning.Type: ApplicationFiled: July 25, 2017Publication date: January 31, 2019Inventors: Eddy Aeloiza, Arun Kadavelugu, Joonas Puukko, Liming Liu, Jukka-Pekka Sjoroos
-
Publication number: 20190032062Abstract: The present invention relates to the field of biotechnology engineering. It provides a recombinant Escherichia coli that can produce fructosylated chondroitin with high yields and the method for constructing the recombinant strain. The present invention discloses a method for constructing an expression plasmid pETM6R1-RBS-glmM-GGGS-glmS that contains a glmM and a glmS gene under regulation of ribosome binding sites. The recombinant plasmid was transformed into E. coli K4 to obtain a recombinant E. coli strain ZQ33 that can produce fructosylated chondroitin up to 3.99 g·L?1 by fed-batch fermentation in a 5-L fermentor, which was increased by 108.90% compared to that of the wild type strain.Type: ApplicationFiled: February 8, 2018Publication date: January 31, 2019Applicant: Jiangnan UniversityInventors: Jing Wu, Quan Zhang, Liming Liu, Xiulai Chen, Jia Liu, Qiuling Luo
-
Patent number: 10131889Abstract: The present invention relates to the field of bioengineering. It provides a Candida antarctica lipase B mutant and its application. The mutant enzyme overcomes the limit of the parent enzyme that can exhibit high enantioselectivity towards (R)-3-TBDMSO glutaric acid methyl monoester only at temperatures below 5° C. The mutant enzyme successfully increased R-ee value at 5-70° C. The mutant D223V/A281S exhibits high R-ee value (>99%), high conversion rate (80%), and high space-time yield (107.54 g L?1 d?1). The present invention lays a foundation for industrial production of (R)-3-TBDMSO glutaric acid methyl monoester using a biosynthesis approach and provide insights into conformational dynamics-based enzyme design.Type: GrantFiled: November 11, 2017Date of Patent: November 20, 2018Assignee: Jiangnan UniversityInventors: Liming Liu, Bin Yang
-
Patent number: 9933805Abstract: Unique systems, methods, techniques and apparatuses of a power converter are disclosed. One exemplary embodiment is an electrical power conversion system comprising a first converter stage, a second converter stage, a third converter stage, and a control system. The first converter stage is operable to boost DC power received from a DC power source. The second converter stage is operable to boost DC power received from the first converter stage. The third converter stage includes an inverter. The control system is structured to receive as input voltage (Vpv) and current (Ipv) output by the DC power source, voltage (Vdc) output by the second controller stage, and voltage (Vac) and a current (Iac) which are output by the third stage to an AC electrical power system, provide a control command for the first converter stage, and process the information of Vdc, Vac and Iac to provide control commands for the inverter switches.Type: GrantFiled: June 27, 2016Date of Patent: April 3, 2018Assignee: ABB Schweiz AGInventors: Liming Liu, Jing Xu
-
Publication number: 20180057802Abstract: The present invention provides a recombinant strain, construction method thereof and a method for producing acid phosphatase using the recombinant strain. In the invention, the phosphatase gene is obtained from Pseudomonas aeruginosa by a molecular biology method, the constructed expression plasmid is transformed into E. coli BL21 (DE3). The purified enzyme and whole cells were used for the conversion of ascorbic acid to ascorbic acid-2-phosphate. Ascorbic acid-2-phosphate can be efficiently produced by controlling the ratio of substrates. When the conversion reaction is performed at pH4.5 under 40° C. for 8 h, the output of ascorbic acid-2-phosphate reaches 54.8 ?/L, the conversion is 42.9% and the space time yield is 6.9 g/L/h.Type: ApplicationFiled: December 21, 2016Publication date: March 1, 2018Inventors: Liming LIU, Wei SONG, Jing WU, Kai ZHENG, Xiulai CHEN
-
Publication number: 20170371367Abstract: Unique systems, methods, techniques and apparatuses of a power converter are disclosed. One exemplary embodiment is an electrical power conversion system comprising a first converter stage, a second converter stage, a third converter stage, and a control system. The first converter stage is operable to boost DC power received from a DC power source. The second converter stage is operable to boost DC power received from the first converter stage. The third converter stage includes an inverter. The control system is structured to receive as input voltage (Vpv) and current (Ipv) output by the DC power source, voltage (Vdc) output by the second controller stage, and voltage (Vac) and a current (Iac) which are output by the third stage to an AC electrical power system, provide a control command for the first converter stage, and process the information of Vdc, Vac and Iac to provide control commands for the inverter switches.Type: ApplicationFiled: June 27, 2016Publication date: December 28, 2017Inventors: Liming Liu, Jing Xu
-
Publication number: 20170227348Abstract: Metal film thickness can be determined using the sheet resistance, resistivity, and temperature coefficient of resistivity for the metal film. Variation in film thickness measurements caused by resistivity can be reduced or eliminated. A probe head may be used for some of the measurements of the metal film. The probe head can include a temperature sensor used during sheet resistance measurements. A wafer on a chuck is heated, such as using the chuck or the probe head, for the measurements.Type: ApplicationFiled: February 24, 2017Publication date: August 10, 2017Inventors: Xianghua Liu, Walter Johnson, Jianli Cui, Lu Yu, Nanchang Zhu, Juli Cheng, Huanglin Li, Liming Liu
-
Publication number: 20170227347Abstract: Metal film thickness can be determined using the sheet resistance, resistivity, and temperature coefficient of resistivity for the metal film. Variation in film thickness measurements caused by resistivity can be reduced or eliminated. A probe head may be used for some of the measurements of the metal film. The probe head can include a temperature sensor used during sheet resistance measurements. A wafer on a chuck is heated, such as using the chuck or the probe head, for the measurements.Type: ApplicationFiled: February 1, 2017Publication date: August 10, 2017Inventors: Xianghua Liu, Walter Johnson, Jianli Cui, Lu Yu, Nanchang Zhu, Juli Cheng, Huanglin Li, Liming Liu
-
Patent number: 9621073Abstract: The scalable cascaded Z-source inverter is able to interface flexibly different distributed renewable energy sources or storages in wide voltage change range, such as wind power, solar power, battery, fuel cell, Ultra-capacitor and so on. The invention facilitates the AC 1 MHz frequency output; therefore high power density can be reached. Z-source network is integrated in each inverter module to wide system operation range, improve high system efficiency, and enhance high system reliability. The invention is applied for PV system to verify the performance.Type: GrantFiled: August 31, 2012Date of Patent: April 11, 2017Assignee: The Florida State University Research Foundation, Inc.Inventors: Liming Liu, Hui Li
-
Publication number: 20160222112Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: December 30, 2015Publication date: August 4, 2016Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20160222111Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: December 30, 2015Publication date: August 4, 2016Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20160222108Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: December 22, 2015Publication date: August 4, 2016Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20160222109Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: December 29, 2015Publication date: August 4, 2016Applicants: Dyax Corp., Biogen Hemophilia Inc.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20160222110Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: December 29, 2015Publication date: August 4, 2016Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan